Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes

NCT02832999 on ClinicalTrials.gov · last registry update 2017-12-26

A small phase 4 — 14 participants, against a typical 75. The sponsor logged completion for September 2016. Primary outcome, as filed: Insulin sentivity. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Yaounde Central Hospital
Sponsor type: Other Gov
Enrollment: 14
Started: 2016-01
Primary completion: 2016-09 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Insulin sentivity

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.